Who is sponsoring NCT04671108?

NCT04671108 is sponsored by Vision Service Plan.

What drugs are being tested in NCT04671108?

Interventions in NCT04671108: Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA).

What condition does NCT04671108 study?

NCT04671108 studies Refractive Error - Myopia Bilateral.

Is NCT04671108 still recruiting?

NCT04671108 is currently completed. Last updated 23 July 2021.

Last reviewed 2021-07-23 · How we verify

NCT04671108: DDHyd

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Clinical Performance of 59% Hioxifilcon A Contact Lenses vs. Marketed Hydrogel Contact Lenses

Completed NA Last updated 23 July 2021

What this trial tests

NA trial testing Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA) in Refractive Error - Myopia Bilateral in 50 participants. Completed in 18 December 2020.

Timeline

11 November 2020

Primary endpoint
18 December 2020

18 December 2020

Quick facts

Lead sponsor	Vision Service Plan
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	11 November 2020
Primary completion	18 December 2020
Estimated completion	18 December 2020
Sites	3 locations across United States

Drugs / interventions tested

Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)

Conditions studied

Refractive Error - Myopia Bilateral — all drugs for Refractive Error - Myopia Bilateral →

Sponsor

Vision Service Plan

Who can join

Adults 18 to 42, any sex, with Refractive Error - Myopia Bilateral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will compare the short-term clinical performance and wearer and practitioner acceptability of a new-to-market spherical daily disposable (DD) hydrogel soft contact lens to a currently marketed spherical DD hydrogel soft contact lens.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Drug Delivery Strategies and Biomedical Significance of Hydrogels: Translational Considerations.
Raina N, Pahwa R, Bhattacharya J, Paul AK, et al · · 2022 · cited 79× · PMID 35335950 · DOI 10.3390/pharmaceutics14030574

Verify or expand the search:

Other trials of Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)

Trials testing the same drug.

NCT04986644 — Clinical Performance of 59% Hioxifilcon A vs. Marketed Hydrogel Contact Lenses in Habitual Hydrogel Wearers · NA · completed

Other Vision Service Plan trials

Trials by the same sponsor.

NCT04986644 — Clinical Performance of 59% Hioxifilcon A vs. Marketed Hydrogel Contact Lenses in Habitual Hydrogel Wearers · NA · completed
NCT04032457 — PAVES Benchmarking Pilot Study of Daily Disposable Contact Lenses · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04671108 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vision Service Plan
Last refreshed: 23 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04671108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing